In interventional studies, mirabegron administration (100 mg/day for four weeks in healthy women, and 50 mg/day in individuals with obesity) led to increases in BAT mass, resting EE, glucose tolerance, and insulin sensitivity102,103. This evidence concerns the gene INS and Obesity.